1-6 of 6
H. Joachim Deeg
Close
Sort by
Journal Articles

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes

Maryam Rafati, Derek W. Brown, Weiyin Zhou, Kristine Jones, Wen Luo, Andrew St. Martin, Youjin Wang, Meilun He, Stephen R. Spellman, Tao Wang, H. Joachim Deeg, Vikas Gupta, Stephanie J. Lee, Yung-Tsi Bolon, Stephen J. Chanock, Mitchell J. Machiela, Wael Saber, Shahinaz M. Gadalla
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7506–7515.
https://doi.org/10.1182/bloodadvances.2023010882
Published: 2023
Includes: Supplemental data
Journal Articles

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation

H. Joachim Deeg
Journal: Blood Advances
Blood Adv (2022) 6 (5): 1623–1627.
https://doi.org/10.1182/bloodadvances.2021004799
Published: 2022
Journal Articles

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Se young Han, Krzysztof Mrózek, Jenna Voutsinas, Qian Wu, Elizabeth A. Morgan, Hanne Vestergaard, Robert Ohgami, Philip M. Kluin, Thomas Kielsgaard Kristensen, Sheeja Pullarkat, Michael Boe Møller, Ana-Iris Schiefer, Linda B. Baughn, Young Kim, David Czuchlewski, Jacobien R. Hilberink, Hans-Peter Horny, Tracy I. George, Michelle Dolan, Nam K. Ku, Cecilia Arana Yi, Vinod Pullarkat, Jessica Kohlschmidt, Amandeep Salhotra, Lori Soma, Clara D. Bloomfield, Dong Chen, Wolfgang R. Sperr, Guido Marcucci, Christina Cho, Cem Akin, Jason Gotlib, Sigurd Broesby-Olsen, Melissa Larson, Michael A. Linden, H. Joachim Deeg, Gregor Hoermann, Miguel-Angel Perales, Jason L. Hornick, Mark R. Litzow, Ryotaro Nakamura, Daniel Weisdorf, Gautam Borthakur, Gerwin Huls, Peter Valent, Celalettin Ustun, Cecilia C. S. Yeung
Journal: Blood Advances
Blood Adv (2021) 5 (10): 2481–2489.
https://doi.org/10.1182/bloodadvances.2020003605
Published: 2021
Includes: Supplemental data
Journal Articles

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL –negative MPN in blast phase

Clinical Trials & Observations
Vikas Gupta, James A. Kennedy, Jose-Mario Capo-Chichi, Soyoung Kim, Zhen-Huan Hu, Edwin P. Alyea, Uday R. Popat, Ronald M. Sobecks, Bart L. Scott, Aaron T. Gerds, Rachel B. Salit, H. Joachim Deeg, Ryotara Nakamura, Wael Saber
Journal: Blood Advances
Blood Adv (2020) 4 (21): 5562–5573.
https://doi.org/10.1182/bloodadvances.2020002727
Published: 2020
Includes: Supplemental data
Journal Articles

Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study

Clinical Trials & Observations
Filippo Milano, Jonathan A. Gutman, H. Joachim Deeg, Eneida R. Nemecek, Joachim Baumgart, Laurel Thur, Ann Dahlberg, Rachel B. Salit, Corinne Summers, Frederick R. Appelbaum, Colleen Delaney
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3302–3310.
https://doi.org/10.1182/bloodadvances.2020002222
Published: 2020
Includes: Supplemental data
Journal Articles

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity

Clinical Trials & Observations
Mary Eapen, Ruta Brazauskas, Michael Hemmer, Waleska S. Perez, Patricia Steinert, Mary M. Horowitz, H. Joachim Deeg
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2095–2103.
https://doi.org/10.1182/bloodadvances.2018021980
Published: 2018